학술논문
1625P Multicenter, randomized, parallel group, phase II study to establish the efficacy and safety of CBP501, cisplatin, and nivolumab for ≥ third-line treatment of patients with exocrine pancreatic cancer and WBC
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S900-S900
Subject
Language
ISSN
0923-7534